RxDoctor Payments DataLook up a doctor →

Jennifer Cribb

Primary Care · Las Vegas, NVNPI 1093047086

Payments from drug & device makers

$6,602in general payments, 2019–2025

Across 340 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$834
  • Astellas Pharma US Inc$743
  • GSK$670
  • Pfizer$601
  • Amgen$488
  • AbbVie$417
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,35696%
  • Education$2464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,602 in reported general payments places this provider in the 95th percentile of 81 primary care providers in Nevada.

See all primary care providers in Nevada

Medicare billing

Part B allowed, 2024
$298,665
Medicare patients
353
Services billed
4,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin48$61,327
OzempicSemaglutide43$58,371
MounjaroTirzepatide45$53,386
EliquisApixaban36$34,216
MyrbetriqMirabegron37$33,983
Nurtec OdtRimegepant Sulfate23$31,808
XareltoRivaroxaban21$24,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$21,291
RexultiBrexpiprazole12$20,485
JanuviaSitagliptin Phosphate20$17,626
Synjardy XrEmpagliflozin/Metformin Hcl12$13,078
Trijardy XrEmpaglifloz/Linaglip/Metformin17$11,066
SymbicortBudesonide/Formoterol Fumarate11$4,280
DayvigoLemborexant11$3,593
Gabapentin155$3,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$211$85,47177 claims
PfizerEliquis, Nurtec Odt, Premarin$601$68,46671 claims
Novo NordiskOzempic$834$58,37143 claims
Lilly USA, LLCMounjaro$401$53,38645 claims
Astellas Pharma US IncMyrbetriq$743$33,98337 claims
Johnson & JohnsonXarelto$152$24,55721 claims
GSKTrelegy Ellipta$670$21,29117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$216$20,48512 claims
MerckJanuvia$39$17,62620 claims
AstraZenecaSymbicort$297$4,28011 claims
Eisai Inc.Dayvigo$35$3,59311 claims
AbbVieSynthroid$417$2,59438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 primary care providers in Nevada.

Other primary care in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →